Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6864210 | 0.78 | FFAR1 (0.41) | FFAR1OPRM1MAPK1 | |
| SCHEMBL6864215 | 0.78 | FFAR1 (0.41) | FFAR1OPRM1MAPK1 | |
| SCHEMBL16208034 | 0.70 | ACHE (0.48) | FFAR1 | |
| SCHEMBL8116830 | 0.70 | FFAR1 (0.47) | FFAR1 | |
| SCHEMBL11724743 | 0.67 | ALDH1A1 (0.48) | FFAR1HTR2BMAPK1 | |
| SCHEMBL12425606 | 0.66 | CARM1 (0.33) | CARM1PRMT6 | |
| SCHEMBL15133572 | 0.66 | CARM1 (0.33) | CARM1PRMT6 | |
| SCHEMBL10154050 | 0.66 | ADRA1D (0.51) | CARM1PRMT6MAPK1 | |
| SCHEMBL9970754 | 0.63 | MAPT (0.49) | CARM1PRMT6MAPK1 | |
| SCHEMBL26241141 | 0.63 | MAPK1 (0.38) | FFAR1OPRM1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |